Join AlphaMaven

The Home Of Hedge Funds

Register For Free Learn More Contact Us

Most Visited Alternative Investment Industry Website. Over 50,000 visitors per month

Hedge Fund Dashboard:

Click to subscribe to our Free Daily Newsletter

Top Hedge Fund News, Member Posts, Hedge Fund Daily Indices and more!

JPMorgan Barely Stifling Guffaws At Wells Fargo’s Presumption
3yrs ago Hedge Fund dealbreaker Views: 384

The stagecoach has a ways to go before the Morgans feel the shock of recognition.

It is Charlie Scharf’s most fervent desire and deeply-felt ambition to turn Wells Fargo into JPMorgan Chase. He’s tried to make it look like the House of Dimon. He’s even injected a little Dimon blood (by marriage) into the operation. Try as he might, however, JPMorgan still doesn’t see the resemblance.

J.P. Morgan analyst Vivek Juneja reiterated the underweight rating he's had on the stock for the past two years, writing in a note to clients that "concerns about dividend cuts have weighed on Wells Fargo recently because it has the highest payout ratio among our banks and also because of remarks by [Federal Reserve] Vice Chair [Randal] Quarles."

And if this spurning gets Wells thinking it might like to look like still another bank, well…

Regarding speculation by some of a merger between Wells Fargo and Goldman Sachs Group Inc., Juneja said any bank acquisition by Wells is "banned by law" as the bank already exceeds the 10% deposit market share limit.

Wells Fargo’s stock sinks further after J.P. Morgan reiterates bearish view amid concerns of dividend cut [MarketWatch]


Today's Hedge Fund Headlines:

Most popular| Most recent
FEATURED MEMBER POST
Andrea Alms Video:  Money In Motion 99 - Immunology Market
Private Equity BrookDell Partners #Video
Goldman Sachs on the largest selling of stocks by hedge funds in 3 months - short sales - TradingView
1w ago Hedge Fund tradingview
Skadden hires Linklaters London finance partner
1w ago Hedge Fund fnlondon
Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
Sign Up Now
FREE NEWSLETTER (140K+ Subscribers)
View Hedge Fund Listings
AlphaMaven Daily Indices
Apr MTD ROR
AlphaMaven Hedge Fund Index:
1.0%
- more -
SPONSORED BY
Be Seen - Advertise With Us
Click to Discuss
FEATURED MEMBER POSTS
Andrea Alms Video:  Money In Motion 99 - Immunology Market
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 101 - Deep Dive - Immunotherapy Cancer Market
- posted by: BrookDell Partners
Exome Worldwide Healthcare Partners - March 2024 Investor Newsletter
- posted by: Worldwide Healthcare Partners
Andrea Alms Video:  Money In Motion 97 - The Chemotherapy Market
- posted by: BrookDell Partners
Ridgedale Commodity Solutions Newsletter - March 2024
- posted by: Ridgedale RMAC Index Plus
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.